The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 3, 2009, Pages 361-362

  Airo, Paolo ^a   Scarsi, Mirko ^a   Malagoli, Alberto ^a   Carella, Graziella ^a   Izzo, Ilaria ^b   Carosi, Giampiero ^b   Torti, Carlo ^b  

^a Rheumatology and Clinical Immunology Service   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; HLA B ANTIGEN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; HLA B*5701 ANTIGEN, HUMAN; HLA-B*5701 ANTIGEN, HUMAN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ALLELE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; ECONOMICS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MASS SCREENING; METHODOLOGY; PHARMACOGENETICS; SENSITIVITY AND SPECIFICITY;

DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MASS SCREENING; PHARMACOGENETICS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 67651031279     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181aa1382     Document Type: Letter

References (14)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300: 555-570.
2. *5701 screening for susceptibility to abacavir hyper-sensitivity. J Antimicrob Chemother. 2007;59: 591-593.
3. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
4. *5701 and a haplotypic Hsp70-HOM variant. Proc Natl Acad Sci U S A. 2004;101;4180-4185.
5. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacoge-nomics. 2004;5:203-211.
6. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979-981.
7. *5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46: 1111-1118.
8. *5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358: 568-579.
9. *5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22:2025-2033.
10. *5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis. 2007;44: 1503-1508.
11. *5701. Clin Infect Dis. 2007;45: 1243-1244.
12. Martin AM, Krueger R, Almeida CA, et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006;16:353-357.
13. Saiki RK, Walsch PS, Levenson CH, et al. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A. 1989;86: 6230-6234.
14. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39: 225-235.